|
Post by veritasfiliatemporis on Nov 1, 2018 7:24:44 GMT -5
Cash is 11 million. That doesn't sound good. + 45 +10 M$
|
|
|
Post by sla55 on Nov 1, 2018 7:27:23 GMT -5
|
|
|
Post by peppy on Nov 1, 2018 7:31:26 GMT -5
Cash is 11 million. That doesn't sound good. Cash at end of 3rd qtr. UTHR Cash is 4th qtr. Thank you. Fifth consecutive quarter with triple digit year-over-year Afrezza Net Revenue growth 3Q 2018 Afrezza Net Revenue was $4.4 million versus $2.0 million in 3Q 2017; 121% growth. Year-to-date Afrezza Net Revenue was $11.5 million versus $4.7 million; 144% growth.3Q 2018 Afrezza Gross Revenue was $8.2 million versus $2.8 million in 3Q 2017; 191% growth. Year-to-date Afrezza 2018 Gross Revenue was $20.1 million versus $7.1 million; 184% growth.3Q 2018 Afrezza TRx grew 51% versus 3Q 2017.
|
|
|
Post by Clement on Nov 1, 2018 7:32:23 GMT -5
How cool is this (from sla's news-release-details)!
"Interest expense on notes was $1.0 million for the third quarter of 2018 compared to $2.3 million for the third quarter of 2017. The $1.3 million or 57% decrease was primarily due to a reduction in the principal debt balances."
|
|
|
Post by mike0475 on Nov 1, 2018 7:33:04 GMT -5
Cash, cash equivalents and restricted cash at September 30, 2018 was $11.0 million compared to $48.4 million at December 31, 2017, primarily due to net cash used in operating activities of $62.7 million, inclusive of $10.0 million received from United Therapeutics in September 2018, primarily offset by $26.4 million of net proceeds from a registered direct offering of 14 million shares of common stock and warrants at a purchase price of $2.00 per share and accompanying warrant.
|
|
|
Post by boytroy88 on Nov 1, 2018 7:33:09 GMT -5
PM isn't reacting... yet, hopefully...
|
|
|
Post by boytroy88 on Nov 1, 2018 7:34:51 GMT -5
PM isn't reacting... yet, hopefully... Last chance at these levels???
|
|
|
Post by awesomo on Nov 1, 2018 7:35:37 GMT -5
Afrezza revenue $11.5M through 9 months, rough estimate of $16-17M for the year. This is way below guidance isn’t it? I remember them adjusting lower to 22M.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Nov 1, 2018 7:35:46 GMT -5
How cool is this (from sla's news-release-details)! "Interest expense on notes was $1.0 million for the third quarter of 2018 compared to $2.3 million for the third quarter of 2017. The $1.3 million or 57% decrease was primarily due to a reduction in the principal debt balances." Look at Q3 '18 COGS vs Q3 '17. Back out the '18 charge and they are the same except sales were much larger. Gives an idea as to variable costs. Break even on Afrezza is around $70mm or so? At minimum, much lower burn rate in '19. Company showing 16 vacant sales territories. Label change the other day, Kendal working on stuff. Inertia to selling Afrezza will be lower in '19. Lots of hard work but more results for efforts in '19. Improving moral, success breeds success.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Nov 1, 2018 7:37:25 GMT -5
Afrezza revenue $11.5M through 9 months, rough estimate of $16-17M for the year. This is way below guidance isn’t it? I remember them adjusting lower to 22M. Yep, and the shorts will pound on that. Not happy but it is what it is. 2019 Afrezza sales will grow at faster rate. More reps, better coverage more tools to sell because of Kendall.
|
|
|
Post by boytroy88 on Nov 1, 2018 7:41:19 GMT -5
Afrezza revenue $11.5M through 9 months, rough estimate of $16-17M for the year. This is way below guidance isn’t it? I remember them adjusting lower to 22M. Your estimate is assuming the last quarter is the average of the first three... That's probably not the case... The last quarter grew faster than the previous two so there's still a chance that they'll meet or even beat guidance.
|
|
|
Post by awesomo on Nov 1, 2018 7:46:02 GMT -5
Afrezza revenue $11.5M through 9 months, rough estimate of $16-17M for the year. This is way below guidance isn’t it? I remember them adjusting lower to 22M. Your estimate is assuming the last quarter is the average other first three... That's probably not the case... The last quarter grew faster than the previous two so there's still a chance that they'll meet or even beat guidance. No it isn’t, I accounted for some growth. Script growth has been extremely slow in 2018. Unless revenue close to triples from $4.3M in Q3 to $11M in Q4, they won’t hit guidance.
|
|
|
Post by boytroy88 on Nov 1, 2018 7:48:03 GMT -5
Your estimate is assuming the last quarter is the average other first three... That's probably not the case... The last quarter grew faster than the previous two so there's still a chance that they'll meet or even beat guidance. No it isn’t, I accounted for some growth. Script growth has been extremely slow in 2018. Unless revenue close to triples from $4.3M in Q3 to $11M in Q4, they won’t hit guidance. That's right...too early in the morning to do math :/
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Nov 1, 2018 7:49:36 GMT -5
Your estimate is assuming the last quarter is the average other first three... That's probably not the case... The last quarter grew faster than the previous two so there's still a chance that they'll meet or even beat guidance. No it isn’t, I accounted for some growth. Script growth has been extremely slow in 2018. Unless revenue close to triples from $4.3M in Q3 to $11M in Q4, they won’t hit guidance. Any idea as to how many sales people that have right now? Thinking they may have slow rolled it a bit to continue developing managed care contracts, burn less cash and knew strategically they had other opportunities coming to fruition later in the year (United, RLS...). Purpose of TV campaign? Drive sales or demonstrate advertising sensitivity to model what a bigger infrastructure could do and pitch it to potential partners?
|
|
|
Post by slugworth008 on Nov 1, 2018 8:33:31 GMT -5
The lights are still on and MNKD is still breathing and breathing a bit easier these days. Al's creature has LIFE! Looking forward to a future forward spilt -
|
|